Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


James P. Brody has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Biomarker Interaction Trap: A Causal Audit of Spurious Discoveries in NHANES

    by James Brody

    Statistical screening of large clinical registries routinely identifies biomarker interactions that appear to predict disease risk. These interactions replicate across independent cohorts, lending false confidence in their validity. We evaluated three such interactions discovered through systematic screening of the National Health and Nutrition Examination Survey (NHANES) and show that each is an artifact of a distinct methodological flaw rather than a genuine biological signal. We describe three failure modes. First, the Hemoconcentration Trap: an apparent statistical interaction between elevated serum albumin and total cholesterol for uncontrolled hypertension disappears after adjusting for hydration status (interaction p-value shifts from < 0.001 to 0.412). Second, the Confounding-by-Indication Trap: an apparent drug-biomarker interaction between low hemoglobin, elevated creatinine, and glycemic failure in statin users turns out to be a disease-severity marker that exists regardless of statin use. Third, the Demographic Reference Range Trap: an apparent protective interaction between uric acid and hemoglobin for diabetes is driven by sex-homogeneous subgroup formation when population-wide percentile thresholds are applied to sex-dimorphic biomarkers. After demographic residualization, this interaction attenuates by 74% in discovery and becomes non-significant in validation. We propose a four-step checklist for auditing biomarker interactions and argue that replication alone cannot establish biological validity when the confounding mechanism is itself reproducible.

  • Open Access

    A compact encoding of the genome suitable for machine learning prediction of traits and genetic risk scores

    by Yasaman Fatapour, James P. Brody

    Genotype to phenotype prediction is a central problem in biology and medicine. Machine learning is a natural tool to address this problem. However, a person’s genotype is usually represented by a few million single-nucleotide polymorphisms and most datasets only have a few thousand patients. Thus, this problem typically has many more predictors than the number of samples (patients), making it unsuitable for machine learning. The objective of this paper is to examine the efficacy of a compact genotype representation, which employs a limited number of predictors, in predicting a person’s phenotype through the application of machine learning. We characterized a person’s genotype using chromosome-scale length variation, a measure that is computed as the average value of reported log R ratios across a portion of a chromosome. We computed these numbers from data collected by the NIH All of Us program. We used the AutoML function (h2o.ai) in binary classification mode to identify the best models to differentiate between male/female, Black/white, white/Asian, and Black/Asian. We also used the AutoML function in regression mode to predict the height of people based on their age and genotype. Our results showed that we could effectively classify a person, using only information from chromosomes 1–22, as Male/Female (AUC = 0.9988 ± 0.0001), White/Black (AUC = 0.970 ± 0.002), Asian/White (AUC = 0.877 ± 0.002), and Black/Asian (AUC = 0.966 ± 0.002). This approach also effectively predicted height. In conclusion, we have shown that this compact representation of a person’s genotype, along with machine learning, can effectively predict a person’s phenotype.


  • Open Access

    Improved breast cancer risk prediction using chromosomal-scale length variation

    by Yasaman Fatapour, James P. Brody

    Introduction: Early diagnosis of breast cancer leads to higher long-term survival rates. The development of a germline genetic test, or polygenic risk score, to identify women at high risk of breast cancer holds the potential to reduce cancer deaths. However, current tests based on SNPs do not perform much better than predictions based on family history and perform significantly worse in populations with non-European ancestry. We have developed an alternative method to characterize a genome, called chromosomal-scale length variation, which can be applied to polygenic risk scores. Objective: The objective of this paper is to characterize a breast cancer genetic risk score based on chromosomal-scale length variation using the NIH All of Us dataset in different self-identified racial groups when trained on different populations. Methods: We used the NIH All of Us dataset to compile a dataset with 4,533 women who have been diagnosed with breast cancer (including 440 who self-identified as Black) and 44,518 women who have not. We acquired, through All of Us, genetic information for each of these women. We computed a set of 88 values for each woman in the dataset, representing the chromosomal-scale length variation parameters. These numbers are average log R ratios for four different segments from each of the 22 autosomes. We used machine learning algorithms to find a model that best differentiates the women with breast cancer from the women without breast cancer based on the set of 88 numbers that characterize each woman’s germline genome. Results: The best model had an AUC of 0.70 (95% CI, 0.67–0.73) in the All of Us population. Women who scored in the top quintile by this model were nine times more likely to have breast cancer when compared to women who scored in the lowest quintile. Conclusion: In conclusion, we found that this method of computing genetic risk scores for breast cancer is a substantial improvement over SNP-based polygenic risk scores. In addition, we compared models trained on populations of only White women and only Black women. We found that the models trained only on White women performed better than models trained only on Black women when tested on only White women. We did not see a significant difference between the two models when tested on only Black women.


  • Open Access

    A compact encoding of the genome suitable for machine learning prediction of traits and genetic risk scores

    by Yasaman Fatapour, James P. Brody

    Genotype to phenotype prediction is a central problem in biology and medicine. Machine learning is a natural tool to address this problem. However, a person’s genotype is usually represented by a few million single-nucleotide polymorphisms and most datasets only have a few thousand patients. Thus, this problem typically has many more predictors than the number of samples (patients), making it unsuitable for machine learning. The objective of this paper is to examine the efficacy of a compact genotype representation, which employs a limited number of predictors, in predicting a person’s phenotype through the application of machine learning. We characterized a person’s genotype using chromosome-scale length variation, a measure that is computed as the average value of reported log R ratios across a portion of a chromosome. We computed these numbers from data collected by the NIH All of Us program. We used the AutoML function (h2o.ai) in binary classification mode to identify the best models to differentiate between male/female, Black/white, white/Asian, and Black/Asian. We also used the AutoML function in regression mode to predict the height of people based on their age and genotype. Our results showed that we could effectively classify a person, using only information from chromosomes 1-22, as Male/Female (AUC=0.9988±0.0001), White/Black (AUC=0.970± 0.002), Asian/White (AUC=0.877± 0.002), and Black/Asian (AUC=0.966± 0.002). This approach also effectively predicted height. In conclusion, we have shown that this compact representation of a person’s genotype, along with machine learning, can effectively predict a person’s phenotype.


  • Open Access

    Ex vivo discovery of synergistic drug combinations for hematologic malignancies

    by Kamran A. Ali, Reecha D. Shah, Anukriti Dhar, Nina M. Myers, Cameron Nguyen, Arisa Paul, Jordan E. Mancuso, A. Scott Patterson, James P. Brody, Diane Heiser


  • Open Access

    Evaluation of a genetic risk score computed using human chromosomal-scale length variation to predict breast cancer

    by Charmeine Ko, James P. Brody

    Introduction: The ability to accurately predict whether a woman will develop breast cancer later in her life, should reduce the number of breast cancer deaths. Different predictive models exist for breast cancer based on family history, BRCA status, and SNP analysis. The best of these models has an accuracy (area under the receiver operating characteristic curve, AUC) of about 0.65. We have developed computational methods to characterize a genome by a small set of numbers that represent the length of segments of the chromosomes, called chromosomal-scale length variation (CSLV). Methods: We built machine learning models to differentiate between women who had breast cancer and women who did not based on their CSLV characterization. We applied this procedure to two different datasets: the UK Biobank (1534 women with breast cancer and 4391 women who did not) and the Cancer Genome Atlas (TCGA) 874 with breast cancer and 3381 without. Results: We found a machine learning model that could predict breast cancer with an AUC of 0.836 95% CI (0.830.0.843) in the UK Biobank data. Using a similar approach with the TCGA data, we obtained a model with an AUC of 0.704 95% CI (0.702, 0.706). Variable importance analysis indicated that no single chromosomal region was responsible for significant fraction of the model results. Conclusion: In this retrospective study, chromosomal-scale length variation could effectively predict whether or not a woman enrolled in the UK Biobank study developed breast cancer.


  • Open Access

    Development of a Machine Learning Model to Predict Recurrence of Oral Tongue Squamous Cell Carcinoma

    by Yasaman Fatapour, Arash Abiri, Edward C. Kuan, James P. Brody

    Despite diagnostic advancements, the development of reliable prognostic systems for assessing the risk of cancer recurrence still remains a challenge. In this study, we developed a novel framework to generate highly representative machine-learning prediction models for oral tongue squamous cell carcinoma (OTSCC) cancer recurrence. We identified cases of 5- and 10-year OTSCC recurrence from the SEER database. Four classification models were trained using the H2O ai platform, whose performances were assessed according to their accuracy, recall, precision, and the area under the curve (AUC) of their receiver operating characteristic (ROC) curves. By evaluating Shapley additive explanation contribution plots, feature importance was studied. Of the 130,979 patients studied, 36,042 (27.5%) were female, and the mean (SD) age was 58.2 (13.7) years. The Gradient Boosting Machine model performed the best, achieving 81.8% accuracy and 97.7% precision for 5-year prediction. Moreover, 10-year predictions demonstrated 80.0% accuracy and 94.0% precision. The number of prior tumors, patient age, the site of cancer recurrence, and tumor histology were the most significant predictors. The implementation of our novel SEER framework enabled the successful identification of patients with OTSCC recurrence, with which highly accurate and sensitive prediction models were generated. Thus, we demonstrate our framework’s potential for application in various cancers to build generalizable screening tools to predict tumor recurrence.


  • Open Access

    Genetic Risk Scores and Missing Heritability in Ovarian Cancer

    by Yasaman Fatapour, James P. Brody

    Ovarian cancers are curable by surgical resection when discovered early. Unfortunately, most ovarian cancers are diagnosed in the later stages. One strategy to identify early ovarian tumors is to screen women who have the highest risk. This opinion article summarizes the accuracy of different methods used to assess the risk of developing ovarian cancer, including family history, BRCA genetic tests, and polygenic risk scores. The accuracy of these is compared to the maximum theoretical accuracy, revealing a substantial gap. We suggest that this gap, or missing heritability, could be caused by epistatic interactions between genes. An alternative approach to computing genetic risk scores, using chromosomal-scale length variation should incorporate epistatic interactions. Future research in this area should focus on this and other alternative methods of characterizing genomes.


  • Open Access

    Genetic Risk Scores and Missing Heritability in Ovarian Cancer

    by James P Brody, Yasaman Fatapour

    Ovarian cancers are curable by surgical resection when discovered early enough. Unfortunately, most ovarian cancers are diagnosed in the later stages. One strategy to identify early ovarian tumors is to screen women who have the highest risk scores. This mini review summarizes the accuracy of different methods used to assess the risk of developing ovarian cancer, including family history, BRCA genetic tests, and polygenic risk scores. The accuracy of these is compared to the maximum theoretical accuracy, revealing a substantial gap. We suggest that this gap, or missing heritability, could be caused by epistatic interactions between genes. An alternative approach to computing genetic risk scores, using chromosomal-scale length variation should incorporate epistatic interactions. Future research in this area should focus on this and other alternative methods of characterizing genomes.